#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	2684	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2291	340.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1495	1495	C	415	C	336	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4134	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4135	299.2	0	.	n	.	0	T695C	SNP	695	695	T	1296	1296	C	303	C	249	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4134	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4135	299.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1938	1938	A	391	A	332	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4134	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4135	299.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2572	2572	C	358	C	302	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4134	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4135	299.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3198	3198	T	336	T,C	293,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4134	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4135	299.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2646	2646	A	372	A,C	309,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	404	folP	852	852	100.0	folP.l6.c4.ctg.1	1884	63.8	1	SNP	p	R228S	1	.	.	682	684	AGC	1249	1251	AGC	104;105;107	A;G;C	88;85;86	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	938	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3833	73.2	1	SNP	p	S91F	0	.	.	271	273	TCC	836	838	TCC	82;82;83	T;C;C	73;73;75	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	938	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3833	73.2	1	SNP	p	D95N	0	.	.	283	285	GAC	848	850	GAC	85;85;84	G;A;C	76;76;73	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	938	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3833	73.2	1	SNP	p	D95G	0	.	.	283	285	GAC	848	850	GAC	85;85;84	G;A;C	76;76;73	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	386	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1686	68.3	0	.	p	.	0	A39T	NONSYN	115	117	GCC	659	661	ACC	108;108;108	A;C;C	91;92;93	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	386	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1686	68.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	674	676	CAC	102;102;102	C;A;C	87;90;93	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	386	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1686	68.3	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	857	859	CAC	98;98;99	C;A;C	82;82;85	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	386	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1686	68.3	1	SNP	p	G45D	0	.	.	133	135	GGC	677	679	GGC	103;104;104	G;G;C	92;92;92	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	246	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1378	53.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	940	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3427	82.2	1	SNP	p	D86N	0	.	.	256	258	GAC	871	873	GAC	106;106;106	G;A;C	87;85;88	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	940	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3427	82.2	1	SNP	p	S87W	0	.	.	259	261	AGT	874	876	AGT	104;103;103	A,C;G;T	85,1;89;85	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	940	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3427	82.2	1	SNP	p	S87I	0	.	.	259	261	AGT	874	876	AGT	104;103;103	A,C;G;T	85,1;89;85	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	940	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3427	82.2	1	SNP	p	S87R	0	.	.	259	261	AGT	874	876	AGT	104;103;103	A,C;G;T	85,1;89;85	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	940	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3427	82.2	1	SNP	p	S88P	0	.	.	262	264	TCC	877	879	TCC	103;104;104	T;C;C	85;87;84	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	788	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3143	75.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1812	1814	GGC	112;111;108	G;G;C	95;92;91	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1318	1320	GCA	113;113;110	G;C;A	92;90;93	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1321	1323	ATC	109;109;109	A;T;C	90;90;89	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1333	1335	GTG	99;98;98	G;T;G	85;81;85	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1333	1335	GTG	99;98;98	G;T;G	85;81;85	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1837	1839	ACC	91;91;91	A;C;C,G	79;77;79,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1891	1893	GCG	85;85;85	G;C,G;G	73;65,1;70	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1891	1893	GCG	85;85;85	G;C,G;G	73;65,1;70	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2014	2016	GGC	97;98;98	G;G;C	85;81;83	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2023	2025	GGC	99;98;98	G;G;C	83;84;80	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	654	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2552	76.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2041	2043	CCG	97;97;95	C;C;G	77;80;77	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	958	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3542	80.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1829	1831	CTG	99;99;99	C;T;G	79;79;84	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	546	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2224	73.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	795	795	C	88	C,T	72,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	95.64	porB1b.l15.c4.ctg.1	1916	81.0	0	.	p	.	0	F135L	NONSYN	403	405	TTT	867	869	CTT	97;97;98	C;T;T	79;78;74	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	95.64	porB1b.l15.c4.ctg.1	1916	81.0	0	.	p	.	0	R143G	NONSYN	427	429	AGA	891	893	GGA	89;88;86	G;G;A	74;71;73	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	95.64	porB1b.l15.c4.ctg.1	1916	81.0	0	.	p	.	0	D171G	NONSYN	511	513	GAT	975	977	GGT	103;104;104	G;G;T	85;84;88	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	95.64	porB1b.l15.c4.ctg.1	1916	81.0	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1029	1031	AGC	104;103;103	A;G;C	86;87;85	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	95.64	porB1b.l15.c4.ctg.1	1916	81.0	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1095	1095	T	103	T	93	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	95.64	porB1b.l15.c4.ctg.1	1916	81.0	1	SNP	p	G120K	0	.	.	358	360	GGT	822	824	GGT	97;98;97	G;G;T	83;81;82	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	95.64	porB1b.l15.c4.ctg.1	1916	81.0	1	SNP	p	A121D	0	.	.	361	363	GCC	825	827	GCC	99;99;99	G;C;C	82;82;85	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	522	porB1b	1035	1035	95.64	porB1b.l15.c4.ctg.1	1916	81.0	1	SNP	p	A121N	0	.	.	361	363	GCC	825	827	GCC	99;99;99	G;C;C	82;82;85	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1750	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5325	98.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2216	2218	AAT	99;100;100	A;A;T	89;88;85	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	266	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1419	55.9	1	SNP	p	V57M	1	.	.	169	171	ATG	660	662	ATG	98;99;100	A;T;G	80;81;80	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
